Development of crispr-CAS guiderna screening platform for allele-specific reduction of mutant huntingtin protein
Ended Project Grant Awarded Last action
- Award ID
- R43NS110161
- Recipient
-
Scribe Therapeutics Inc. UEI E9LNGD3EP3H8
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- -$299,700
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Funding
-
- -$149,850.00 Federal
- -$149,850.00 Non-federal
- Place of performance
- Berkeley, CA 94720, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$149,850 | $0 | |
| Amendment | -$149,850 | -$149,850 | |
| Amendment | $0 | $0 | |
| Original award | $149,850 | $0 |
Quick answers
Who received award R43NS110161?
R43NS110161 was awarded to Scribe Therapeutics Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on February 15, 2019.
How much is award R43NS110161 worth?
Obligations on R43NS110161 net to -$299,700: -$149,850 in federal funding and -$149,850 in non-federal funding: more has been deobligated than obligated.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award